Citations 1
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Gopal, Ajay K. , Chen, Robert , Smith, Scott E. , Ansell, Stephen M. , Rosenblatt, Joseph D. , Engert, Andreas , Larsen, Emily K., Chi, Xuedong, Sievers, Eric L. , Younes, Anas , Savage, Kerry J. , Connors, Joseph M. , Sievers, Eric L , Gopal, Ajay
Blood | December 23, 2014 | Volume: 125 | Issue: 8 | Pages: 1236-1243
Key PointsA total of 47% of patients who achieved CR on brentuximab vedotin remain progression-free after being followed a median of 53 months. Younger age, less functional impairment, and lower disease burden at baseline were associated with CR and prognostic for longer survival.